Innovad Group acquired by PAI PARTNERS
Context
A control buyout transaction has been agreed by private equity firm PAI Partners to acquire Innovad Group from IK Partners, initiating the next strategic expansion cycle for the specialty animal feed additives business. The transaction provides a full monetization event for the seller's IK IX Fund, which held its equity position since 2021. In conjunction with the buyout, the incumbent leadership team headed by Chief Executive Officer Ben Letor is reinvesting alongside the incoming financial sponsor to ensure management continuity and execute the long-term roadmap. Under the prior holding period, the platform delivered consistent double-digit revenue growth, commercialized the proprietary Myco-Marker biomonitoring diagnostic tool, and successfully integrated three strategic add-on acquisitions that broadened its phytogenic capabilities. At the time of the deal, the Belgium-headquartered company operates six production facilities, combining three proprietary manufacturing sites in Belgium, Brazil, and Italy with specialized tolling partners in Switzerland and Italy, serving 900 customers across 75 countries. The value creation plan established by PAI Partners leverages its domain expertise in food, ingredients, and animal nutrition to accelerate organic commercial momentum, increase scientific development capabilities, and execute selective cross-border add-ons. Closing of the deal is targeted for the first quarter of 2026, subject to customary closing conditions.
In the past, the company underwent an LBO led by Ik Partners in 2021, and continued an active consolidation strategy by notably acquiring Herbonis (2023).
Innovad Group, which reported an EBITDA margin of [members only] in 2023, is valued in this transaction at an EV/EBITDA multiple of [members only], to compare with the average currently observed in the Healthcare & Pharma sector (14.3x).
-> Deep-dive in Healthcare & Pharma market trends
Target
Innovad Group is a globally operating supplier of specialty additives for animal feed, concentrating on poultry, ruminant and swine species. Its portfolio comprises high‑value solutions that support gut health, mycotoxin mitigation and immune function, with a pronounced emphasis on phytogenic and biomonitoring technologies. Headquartered in Antwerp, Belgium, the company serves roughly 900 customers across 75 markets. Production capacity is vertically integrated through three owned facilities in Belgium, Brazil and Italy, complemented by toll‑manufacturing partnerships in Switzerland and Italy. Innovad’s R&D platform drives the development of novel nutraceutical ingredients and a proprietary mycotoxin biomonitoring tool. The firm pursues organic expansion, strategic acquisitions and continuous enhancement of its development platform to reinforce its position as a leading specialist in animal nutrition additives.
Ent. Value
€100–200M
Equity Value
[members only]
Multiples
EV / Revenue
[members only]
EV / EBITDA
[members only]
EV / EBIT
[members only]
Historical Financials (EUR)
Other operations with Innovad Group
Other operations with Innovad Group
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 04/2023 | Innovad Group | Herbonis | SWITZERLAND | Animal Health |
| 02/2021 | IK PARTNERS | Innovad Group | BELGIUM | Animal Health |
Similar deals in Life Sciences
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 09/2025 | INVESTCorporate | DCC HEALTHCARE | UNITED KINGDOM | CDMO |
| 09/2025 | CAPVEST PARTNERS | STADA | GERMANY | Generics / Labs |
| 08/2025 | TERUMO | ORGANOX | UNITED KINGDOM | Medical Devices |
| 08/2025 | LGT CAPITAL PARTNERS | NEMERA | FRANCE | Medical Consumables |
| 08/2025 | WARBURG PINCUS | SEBIA | FRANCE | Diagnostic Equipment |
| 07/2025 | PATRICIA INDUSTRIES | NOVA BIOMEDICAL | UNITED STATES | Diagnostic Equipment |
| 07/2025 | BC PARTNERS | BIOGARAN | FRANCE | Pharma & Biotech |
| 05/2025 | OTTOBOCK | MATTON ORTHOMEDI | BELGIUM | Implants & Prosthetics |
| 05/2025 | IK PARTNERS | BIOBANK | FRANCE | Implants & Prosthetics |
| 04/2025 | PATIENT SQUARE CAPITAL | PATTERSON COMPANIES | UNITED STATES | Medical Consumables |
Other operations with PAI PARTNERS
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 06/2026 | PAI PARTNERS | ARLETTIE | FRANCE | Specialized Retail |
| 05/2026 | PAI PARTNERS | MECAER AVIATION GROUP | ITALY | Engines & Systems |
| 10/2025 | PAI PARTNERS | CYRUS | FRANCE | Wealth & Asset Management |
| 10/2025 | PAI PARTNERS / ADIA | FRONERI | UNITED KINGDOM | Food Products |
| 01/2025 | PAI PARTNERS / ADIA | ALVEST | FRANCE | Aerospace, Naval & Defense |
| 03/2024 | PAI PARTNERS | BEAUTYNOVA | ITALY | Hygiene & Beauty Brands |
| 07/2023 | PAI PARTNERS | INFRA GROUP | BELGIUM | IT Services |
| 06/2023 | PAI PARTNERS | ECF GROUP | FRANCE | Hospitality Supplies |
| 05/2023 | PAI PARTNERS | LOOPING GROUP | FRANCE | Leisure Facilities |
| 04/2023 | PAI PARTNERS | EUROPEAN PIZZA GROUP (EPG) | GERMANY | Food Products |
REFERENCES
Revenue range: €100–200M
EBITDA range: €25–50M
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Innovad Group by PAI PARTNERS are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Target: innovad group
Acquirer: pai partners